LBA330 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial). (17th December 2018) - Rozeman, E A; Sikorska, K; van de Wiel, B A; Fanchi, L F; Krijgsman, O; van Thienen, H V; Pronk, L M; Broeks, A; Grijpink-Ongering, L; Ter Meulen, S; Bruining, A; Klop, W M C; et al.